Biotech CEO Compensation: The Real Inflection Point
The real inflection point in biotech CEO compensation isn’t between early and late clinical trials. It’s the leap from pre-clinical to clinical. In this data drop, pulled directly from the Thelander Platform, we looked at how median total cash, founder and non-founder equity changes across biotech stages of development. Pre-Clinical → ClinicalMedian total cash: $329,067 […]
AI in Venture Capital and Private Equity: How Firms Differ
Using data from the Thelander AI in VC report (available on the Thelander Platform for no charge), we looked at how AI in venture capital and private equity is being used in very different ways — and the data shows a clean split by firm type. VC firms are more likely to use AI for […]